TPPP3 Stabilizes Microtubules to Drive Cisplatin Resistance in Ovarian Cancer Cell Models

Michigan State University investigators used cisplatin-resistant ovarian cancer cell lines and correlated TPPP3 expression with clinical outcomes in a retrospective patient cohort. They measured microtubule dynamics via tubulin polymerization assays and tracked cell viability after cisplatin or carboplatin exposure. Cells with higher TPPP3 maintained microtubule integrity despite drug exposure; siRNA-mediated TPPP3 depletion increased apoptosis rates and lowered IC50 values for cisplatin by roughly twofold in resistant lines.

This mechanism extends beyond canonical DNA-damage repair and aligns with observed patterns of rapid recurrence in high-grade serous ovarian carcinoma after initial platinum response. TPPP3 appears to rewire the tubulin code, enabling structural adaptation that protects cells from both DNA and cytoskeletal insults. Such adaptation may partly explain why platinum doublets lose durability faster in ovarian than in testicular germ-cell tumors despite similar initial response rates.

Next steps include development of selective TPPP3 inhibitors and prospective validation of TPPP3 as a resistance biomarker in ongoing platinum-based trials. Parallel work will test whether the same axis operates in other microtubule-dependent cancers such as triple-negative breast cancer.

The study remains limited to cell-line and xenograft models; no human interventional data yet exist.